The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
News|Articles|May 2, 2004
- Pharmaceutical Technology-05-02-2004
- Volume 28
- Issue 5
Prepare for Bar Coding
Author(s)Hallie Forcinio
Drug makers and their suppliers will need good planning and organization to meet the new bar coding requirements for drug products used in hospitals.
Advertisement
Articles in this issue
over 22 years ago
In The Spotlight-May 2004over 22 years ago
FDA Eyes Manufacturing Innovation to Boost Drug Developmentover 22 years ago
aaiPharma Situation Underscores The Need for Due Diligenceover 22 years ago
Excipient Functionalityover 22 years ago
May 2004Advertisement
Related to this article
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Improving Oral Peptide Delivery Through Structural Modifications
2
Regulatory Roundup—October 2026: FDA Advances Rare Disease Development and Transparency Efforts
3
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
4
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
5